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Summary
 
Interleukin (IL)-5 has been shown to activate many signaling molecules in eosinophils, but
their functional relevance remains unknown. We have examined the functional relevance of
Lyn, Jak2, and Raf-1 kinases in eosinophil survival, upregulation of adhesion molecules and
degranulation. To this goal we used Lyn and Raf-1 antisense (AS) oligodeoxynucleotides
(ODN) to inhibit the expression of these proteins and tyrphostin AG490 to specifically block
the activation of Jak2. We have demonstrated that all three kinases are important for IL-5–
induced suppression of eosinophil apoptosis. However, Lyn and Jak2 tyrosine kinases are not
important for the upregulation of CD11b and the secretion of eosinophil cationic protein. In
contrast, Raf-1 kinase is critical for both these functions. This is the first identification of specific
signaling molecules responsible for three important functions of eosinophils. We have estab-
lished a central role for Raf-1 kinase in regulating eosinophil survival, expression of 
 
b
 
2
 
 integrins
and degranulation. Further, there appears to be a dissociation between two receptor-associated
tyrosine kinases, i.e., Lyn and Jak2, and the activation of Raf-1 kinase. The delineation of the
functional relevance of signaling molecules will help design therapeutic approaches targeting
specific eosinophil function.
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E
 
osinophils are major inflammatory effector cells, with
blood and tissue eosinophilia being a feature of many
allergic disorders (1). Activated eosinophils can perform a
variety of specialized cellular functions, including cellular
adhesion, chemotaxis, generation of reactive oxygen me-
tabolites, and secretion of cytotoxic enzymes (2). During an
allergic response, after exposure to a wide range of activa-
tors and chemotactic factors, eosinophils attach to the en-
dothelial wall of the blood vessel at the site of the allergic
reaction. The process of cell attachment and tissue localiza-
tion is mediated by families of cell adhesion molecules that
are expressed on both eosinophils and vascular endothe-
lium (3). Eosinophils then migrate out of the bloodstream
into tissue and degranulate readily, releasing cytotoxic
products such as eosinophil cationic protein (ECP)
 
1
 
 and
major basic protein. Interleukin-5 is the principal regula-
tory cytokine that modulates all described functions of
eosinophils. First, it stimulates differentiation of eosinophils
from bone marrow cells leading to blood eosinophilia (4).
Second, it upregulates the expression of 
 
b
 
2
 
 integrins, lead-
ing to increased recruitment of eosinophils from circulation
(5). By inhibiting apoptosis, IL-5 prolongs survival of eo-
sinophils resulting both in blood and tissue eosinophilia (6).
Finally, IL-5 primes eosinophils for degranulation and re-
lease of reactive oxygen metabolites (7).
The exact mechanism of how IL-5 stimulates functions of
eosinophils is poorly understood. The earliest signaling
events to occur after stimulation of the IL-5 receptor by the
ligand involve the phosphorylation and activation of series of
protein tyrosine kinases, including Lyn, Syk, Jak2, and Fyn
(8–11). The consequence of activation of tyrosine kinases is
the propagation of signal through the Ras-Raf-1–mitogen-
activated protein (MAP) kinase pathway and the Jak-STAT
pathway. Recently, Yosefi et al. (11) have shown that Lyn
and Syk tyrosine kinases are necessary for IL-5–induced inhi-
bition of apoptosis in eosinophils. We have reported the re-
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Abbreviations used in this paper:
 
 AS, antisense; ECP, eosinophil cationic
protein; ERK, extracellular signal-regulated kinase; MAP kinase, mito-
gen-activated protein kinase; ODN, oligodeoxynucleotide; PAF, platelet-
activating factor; SS, sense.
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quirement for SHP-2 tyrosine phosphatase in IL-5–stimu-
lated prolongation of eosinophil survival (12). To date, these
are the only reports showing requirement of signaling mole-
cules for IL-5–induced function of eosinophils.
The role of Jak2, Raf-1, MEK, and MAP kinases in me-
diating diverse cellular functions such as prolongation of
eosinophil survival and activation is not known. An ap-
proach using a dominant negative mutant indicated a role
for Jak2 in GM-CSF–induced cell proliferation (13). Fur-
ther, depletion of Raf-1 kinase by antisense oligodeoxynu-
cleotides resulted in inhibition of GM-CSF and IL-3–induced
proliferation and colony formation in leukemic cell lines
(14). The latter findings indicate that Raf-1 kinase is neces-
sary for activation of different cellular functions. In this
study we took advantage of newly synthesized specific in-
hibitors and/or antisense oligodeoxynucleotides to alter ac-
tivation or expression of the tyrosine kinases Jak2 and Lyn
and the serine/threonine kinase Raf-1 in human eosino-
phils. Having such altered cells, we asked about their ability
to respond to IL-5 with prolongation of survival, upregula-
tion of CD11b adhesion molecule and priming for ECP re-
lease. Our findings revealed different requirements of the
studied kinases for mediating IL-5–induced survival and ac-
tivation of eosinophils.
 
Materials and Methods
 
Reagents.
 
Percoll was purchased from Pharmacia Biotech (Pis-
cataway, NJ). The mAb against anti-phosphotyrosine (clone 4G10)
was obtained from the Upstate Biotechnology Inc. (Lake Placid,
NY). Rabbit polyclonal anti-MAP/extracellular signal-regulated
kinase (ERK)2, anti-Jak2, anti-Lyn, and anti–Raf-1 antibodies
were purchased from Santa Cruz Biotechnology (Santa Cruz, CA).
Mouse monoclonal FITC-conjugated anti-CD11b and its isotype
control antibody were obtained from Sigma Chemical Co. (St.
Louis, MO). The Jak2 inhibitor tyrphostin AG490 was purchased
from Calbiochem-Novabiochem Corp. (La Jolla, CA), and resus-
pended in DMSO. Enhanced chemiluminescence detection system
was purchased from Amersham Corp. (Arlington Heights, IL).
 
Eosinophil Purification.
 
Peripheral blood for eosinophil purifi-
cation was obtained from subjects with mild to moderate eosino-
philia (6–12%). Eosinophils were isolated by sedimentation with
3% hydroxyethyl starch followed by centrifugation on discontin-
uous Percoll gradients according to the method of Gartner (15) as
described previously. The cells were further purified by negative
selection using anti-CD16 immunomagnetic beads (Miltenyi
Biotec, Sunnyvale, CA). Eosinophils (
 
.
 
99% purity) were then
suspended in RPMI 1640 in tubes coated with 3% human serum
albumin.
 
Preparation of Cytosolic Cell Extracts and Immunoprecipitation.
 
Eosinophils (1–4 
 
3
 
 10
 
6
 
) were incubated with IL-5 at a concen-
tration of 10
 
2
 
10
 
 M or medium at 37
 
8
 
C for 5 min or as indicated
in the text. The stimulation was terminated by addition of 1 vol
of ice-cold PBS containing 1 mM Na
 
3
 
VO
 
4.
 
 The cells were pel-
leted by centrifugation, washed rapidly with PBS and lysed in a
buffer containing 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM
EGTA, 0.25% sodium deoxycholate, 1 
 
m
 
M PMSF, 1 
 
m
 
M
Na
 
3
 
VO
 
4
 
, 1 mM NaF, 0.7% Triton X-100, and 1 
 
m
 
g/ml of apro-
tinin, leupeptin, and pepstatin. After an incubation on ice for 10
min, the lysates were passed several times through a 26-gauge
needle and detergent-insoluble materials were removed by cen-
trifugation at 4
 
8
 
C at 12,000 
 
g
 
. The protein concentration was de-
termined using bicinchoninic acid assay (Pierce Chemical Co.,
Rockford, IL). Cell lysates were then resolved on SDS-PAGE
and subjected to Western blotting for detection of Lyn, Raf-1,
and ERK-2 kinases. In other experiments cell lysates were immu-
noprecipitated with anti-Jak2, anti-Lyn, or anti–ERK-2 antibod-
ies to study kinase phosphorylation. For this purpose, the cell ly-
sates were precleared by incubation with 20 
 
m
 
l of the Protein A/G
Plus Agarose (Santa Cruz Biotechnology) for 2 h. After removal
of the beads, the lysates were incubated with an appropriate anti-
body and Protein A/G Plus Agarose for 4 h at 4
 
8
 
C. The immu-
noprecipitates were washed three times with the cold lysis buffer
and boiled in the Laemmli sample buffer.
For the autophosphorylation assay anti-Lyn immunoprecipi-
tates were suspended in 20 
 
m
 
l kinase buffer (10 mM Hepes, pH
7.4, 50 mM NaCl, 5 mM MgCl
 
2
 
, 5 mM MnCl
 
2
 
, and 0.1 mM
Na
 
3
 
VO
 
4
 
) with 0.25 mCi/ml 
 
g
 
-[
 
32
 
P]ATP for 60 min at room
temperature. The reaction was stopped by washing immunopre-
cipitates three times with the lysis buffer and by adding the Laem-
mli’s sample buffer. The kinase reaction products were then ap-
plied to SDS-PAGE and autoradiography.
 
Gel Electrophoresis and Immunoblotting.
 
SDS–polyacrylamide gels
were prepared according to the Laemmli protocol and used for
immunoblotting. The concentration of polyacrylamide was 7 or
12% depending on the molecular mass range of the proteins stud-
ied. Gels were blotted onto Hybond membranes for Western
blotting using the enhanced chemiluminescence system. Blots
were incubated in a blocking buffer containing 5% BSA in TBST
buffer (20 mM Tris-base, 137 mM NaCl, pH 7.6, and 0.05%
Tween 20) for 1 h followed by incubation in the primary Ab (0.1
 
m
 
g/ml) for 1 h. After washing five times in TBST buffer, blots
were incubated for 30 min with a HRP-conjugated secondary
antibody (0.1 
 
m
 
g/ml) directed against primary Ab. The blots
were developed with the enhanced chemiluminescence substrate
according to manufacturer’s protocol. In some experiments blots
were reprobed with another Ab after stripping in a buffer of 62.5
mM Tris-HCl, pH 6.7, 100 
 
m
 
M 2-mercaptoethanol, and 2%
SDS at 50
 
8
 
C for 30 min.
 
Antisense Oligodeoxynucleotides.
 
Two 15-mer Lyn sense (SS)
and antisense (AS) oligodeoxynucleotides (ODN) were synthe-
sized by Operon Technologies (Alameda, CA) based on previ-
ously published sequence information (11). These oligodeoxynu-
cleotides have been reported to decrease the expression of Lyn in
human eosinophils (11). Sequences used were as follows: AS Lyn
(CATATTTCCCGCTCG) and SS Lyn (CGAGCGGGAA-
ATATG). Two 18-mer Raf-1 ODN, AS (TCCCTGTATGT-
GCTCCAT) and SS (ATGGAGCACATACAGGGA), were
synthesized according to a published report that has proven to
block the expression of Raf-1, but not A-Raf, and inhibit GM-
CSF–dependent cell proliferation (14). The ODNs were phos-
phorothioate modified and resuspended in sterile H
 
2
 
O at 100 
 
m
 
M
concentration.
 
Stimulation of Eosinophils.
 
Purified eosinophils were suspended
at 10
 
6
 
/ml in RPMI 1640 and cultured in duplicate in the pres-
ence of ODNs or inhibitors at appropriate concentrations. All
cultures and assays were performed in wells or tubes coated with
3% HSA (Sigma Chemical Co.). After a 6-h incubation, eosino-
phils were counted and cultured with IL-5 (10
 
2
 
10
 
M) for 1.5 h or
as indicated in the text. At this time duplicates were lysed and
subjected to immunoblotting for appropriate kinase expression or
phosphorylation. After treatment with IL-5, cells were washed,
counted, and resuspended in duplicate in RPMI 1640 without 
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IL-5, FCS, inhibitors and ODNs for survival assay (0.5 
 
3
 
 10
 
6
 
/
ml), degranulation assay (0.2 
 
3
 
 10
 
6
 
/ml), or flow cytometric anal-
ysis of CD11b expression (0.5 
 
3
 
 10
 
6
 
/ml). All four assays were
performed simultaneously on eosinophils from the same donor.
 
Survival Assay.
 
For survival studies, eosinophils (0.5 
 
3
 
 10
 
6
 
cells/ml) were incubated with ODNs or inhibitors for 6 h or as
indicated in the text and then stimulated with IL-5 (10
 
2
 
10
 
 M) for
1.5 h. Subsequently, the cells were cultured for 32 h. The relative
number of dead cells was determined by uptake of 5 mM propid-
ium iodide (Sigma Chemical Co.) as determined under a fluores-
cence microscope.
 
Flow Cytometry.
 
Eosinophils (0.5 
 
3
 
 10
 
6
 
 cells/ml) were incu-
bated in the presence or absence of IL-5. After 1.5 h of stimula-
tion, eosinophils were washed in FACS buffer (HBSS containing
1% BSA and 0.1% NaN
 
3
 
) and stained with an anti–human
CD11b FITC-conjugated mAb or with isotype control for 1 h at
4
 
8
 
C. The cells were finally washed in the FACS
 
Ò
 
 buffer, fixed
with 1% paraformaldehyde and 10,000 cells were analyzed by sin-
gle-color flow cytometry on a FACScan
 
Ò
 
 (Becton Dickinson,
San Jose, CA).
 
Degranulation Assay.
 
Eosinophils were primed with IL-5 and
then stimulated with a suboptimal dose of PMA or platelet-acti-
vating factor (PAF) that did not cause degranulation on its own.
In brief, after stimulation with IL-5 or buffer for 1.5 h, eosino-
phils were incubated in RPMI 1640 (0.2 
 
3
 
 10
 
6
 
 cells/ml) with
PMA (0.1 ng/ml) or PAF (10
 
2
 
8 
 
M) for 30 min. After incubation,
supernatants were collected and frozen at 
 
2
 
70
 
8
 
C until assayed for
ECP by radioimmunoassay (Pharmacia Biotech).
 
Statistical Analyses.
 
Results are expressed as mean 
 
6
 
 SD. All
statistical analyses were performed using Student’s paired 
 
t
 
 test.
 
 P
 
,
 
0.05 was considered significant.
 
Results
 
Effect of AS ODNs on Lyn Kinase Expression.
 
One of the
earliest events that occurs after IL-5 stimulation is the acti-
vation and phosphorylation of the receptor-bound Lyn
tyrosine kinase. This kinase has been already shown to be
essential for mediating IL-5–dependent inhibition of apop-
tosis in human eosinophils. To determine the role of Lyn
kinase in IL-5–induced function of eosinophils, first we
evaluated the effect of Lyn AS ODN on the tyrosine kinase
expression. Since eosinophils are terminally differentiated
cells with a 3–4-d life span, the use of AS ODN is the most
practical method to specifically alter expression of Lyn ki-
nase. As demonstrated in Fig. 1, eosinophils exposed to
10 
 
m
 
M AS ODN for 6 h expressed little or no detectable
p53/p56 Lyn kinase, whereas SS ODN did not alter Lyn
level. The AS ODN used in our assay did not alter expres-
sion of a downstream signaling molecule MAP/ERK2 ki-
nase (Fig. 1) and another tyrosine kinase Jak2 (data not
shown). Higher concentrations (15 
 
m
 
M) of both AS and SS
ODN nonspecifically inhibited both Lyn and ERK2 ex-
pression. For this reason all experiments were performed
with 10 
 
m
 
M concentration of Lyn ODN. The viability of
eosinophils assessed at this time (immediately before stimu-
lation with IL-5) always exceeded 90% and was not differ-
ent from control samples, indicating that at 10 
 
m
 
M concen-
tration the ODNs were not toxic to the cells.
 
Effect of Tyrphostin AG490 on Jak2 Inhibition.
 
We exam-
ined the biological relevance of activation of Jak2 by IL-5.
For this purpose eosinophils were treated with AG490 (25
and 50 
 
m
 
M) for 6 h (19). The inhibitor at a concentration
 
,
 
50 
 
m
 
M was not toxic to eosinophils. More than 90% of
eosinophils were viable after 6 h of incubation with
AG490. At 25 
 
m
 
M concentration, AG490 completely
blocked IL-5–induced tyrosine phosphorylation of Jak2
(Fig. 2 
 
A
 
). In contrast, preincubation of eosinophils with
AG490 at 25–50 
 
m
 
M concentrations had no effect on IL-
5–induced tyrosine phosphorylation of p53 and p56 Lyn
kinases (Fig. 2 
 
B
 
). We also studied the effect of AG490 on
Lyn kinase activation. Activated Lyn kinase has previously
been shown to undergo autophosphorylation. AG490 at 25
 
m
 
M concentration did not affect autophosphorylation of
Lyn kinase (Fig. 2 
 
B
 
, 
 
right
 
), confirming its specificity for
Jak2 kinase at low concentrations (19). Interestingly, at
50 
 
m
 
M concentration of AG490 some inhibition of Lyn
autophosphorylation was noted. In subsequent experiments
we used a 25 
 
m
 
M concentration of AG490.
 
Effect of ODN on Raf-1 Expression.
 
We previously re-
ported that IL-5 stimulated the phosphorylation and activa-
tion of Raf-1 kinase in eosinophils. To assess the role of
Raf-1 kinase in transducing signals for eosinophil function,
we performed several sets of experiments using Raf-1 AS
ODN. First, we asked, whether the treatment with AS
ODN had any effect on the expression of Raf-1 and a
downstream signaling molecule, ERK2. As shown on Fig.
3 
 
a
 
, Raf-1 AS, at 7.5 
 
m
 
M concentration, almost completely
inhibited the expression of Raf-1 without affecting ERK2
expression. The SS ODN did not inhibit Raf-1 expression.
Next, we studied the effect of Raf-1 AS ODN on ERK2
activation. Eosinophils treated with medium or SS ODN
showed tyrosine phosphorylation of ERK2 upon stimula-
tion with IL-5. However, this tyrosine phosphorylation
was completely inhibited by the AS ODN (Fig. 3 
 
b
 
, 
 
left
 
).
When the membrane was reprobed with the anti–ERK-2
antibody, we found that there was no change in ERK-2
expression after ODN treatment (Fig. 3 
 
b
 
, 
 
right
 
). The re-
sults suggest that Raf-1 is necessary for phosphorylation
and perhaps activation of ERK-2 kinase. In a separate ex-
periment, the necrotic and apoptotic effects of various
treatments were studied by flow cytometric analysis of an-
nexin V and 7-amino actinomycin D (7-AAD)-stained
Figure 1. The effect of Lyn
AS ODN on Lyn and ERK-2
kinases expression. Purified eo-
sinophils were incubated with
Lyn antisense (AS) or sense (SS)
ODN for 6 h. The cells were
then washed and lysed. The ly-
sates were electrophoresed, trans-
ferred to Hybond membrane,
and then Western blotted with
anti-Lyn and anti–ERK-2 anti-
bodies. The blot was developed with the enhanced chemiluminescence
system. Lyn AS ODN at 10 mM concentration blocked the expression of
Lyn but not ERK-2 kinase (n 5 3). At 15 mM concentration both AS
and SS ODN inhibited the expression of the kinases. 
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cells. The percentage of cells showing necrotic death was
,1% in AS ODN- and AG490-treated cells and was not
different from control buffer–treated cells. Both Lyn and
Raf-1 AS ODN as well as AG490 reversed the antiapop-
totic effect of IL-5 on eosinophils (data not shown).
Having established specific inhibition of Lyn, Jak2, and
Raf-1 kinases, we studied the effect of the AS ODN and
AG490 on eosinophil survival, upregulation of CD11b ad-
hesion molecule and the release of eosinophil cationic pro-
tein. In all subsequent experiments, eosinophils were prein-
cubated with the ODN or AG490 for 6 h and then
stimulated with IL-5 for 1.5 h. The cells were then ali-
quoted for three separate and parallel experiments: (a) sur-
vival assay after 32 h; (b) measurement of CD11b upregu-
lation by flow cytometry; and (c) ECP secretion after
stimulation with a subthreshold concentration of PMA.
The Effect of AS ODN and AG490 on Eosinophil Survival.
After preincubation with the inhibitors (ODN and AG490)
and stimulation with IL-5, eosinophils were resuspended in
RPMI 1640 without IL-5, inhibitors, and FCS. We ex-
cluded FCS from this stage of experiment because serum
has been shown to alleviate the requirement for the Ras
pathway for GM-CSF dependent viability and proliferation
in mutant cells with bc receptor lacking amino acid resi-
dues 626–763 (17). The viability of the cells cultured with-
out serum was 69 6 5% when assessed 32 h after stimula-
tion with IL-5. In contrast to IL-5–stimulated cells, there
was 33 6 7% viable cells in samples incubated with me-
dium alone in lieu of IL-5 (Fig. 4 A). Lyn AS ODN
blocked the ability of IL-5 to prevent eosinophil death (35 6
5% vs. 74 6 7% vs. 69 6 5% for AS-, SS-, and medium-
treated cells, respectively, P ,0.01). The results indicate a
critical role of Lyn kinase in IL-5–induced survival of eo-
sinophils and confirm a previously published report (11).
The incubation of eosinophils with AG490 blocked the
IL-5–induced prolongation of eosinophil survival (Fig. 4
B). There were 31 6 6% viable eosinophils 32 h after stim-
ulation with IL-5 in samples pretreated with AG490. The
dead cells had characteristics of apoptosis by microscopic
examination. Similar results were obtained with a broad
spectrum tyrosine kinase inhibitor, herbimycin A (Fig. 4
B). At 2 mM concentration, herbimycin A blocked both
Lyn and Jak2 tyrosine phosphorylation in eosinophils in
our control immunoblottings. As expected, this inhibitor
blocked IL-5–induced prolongation of viability to a degree
similar to that observed with AG490 and Lyn antisense
ODN. Like Lyn AS ODN and AG490, Raf-1 AS ODN
abrogated the IL-5–induced prolongation of eosinophil
survival (34 6 9% vs. 74 6 7% in control cells; Fig. 4 C).
The Effect of AS ODN and AG490 on CD11b Expres-
sion. We examined the effect of the AS ODN and
AG490 on IL-5–induced upregulation of CD11b adhesion
molecule. CD11b/CD18 complex is constitutively ex-
pressed on eosinophils and its surface density can be upreg-
ulated by stimulation with IL-5 and GM-CSF. Indeed, a
considerable upregulation of CD11b expression was found
as early as 60 min after stimulation with IL-5, reaching the
peak at 1.5 h. This increase in CD11b was not inhibited in
cells treated with Lyn AS or SS ODN indicating that Lyn
was not important in this process (Fig. 5 A). Similarly,
Figure 2. The effect of AG490 on IL-5–induced tyrosine phosphoryla-
tion of Jak2 and Lyn and autophosphorylation of Lyn kinase. Eosinophils
were pretreated with AG490 for 6 h and then stimulated with IL-5. The
cells were lysed and immunoprecipitated with antibodies against p53/56
Lyn or Jak2 kinases. The immunoprecipitates were immunoblotted with
an antiphosphotyrosine antibody. Further, the anti-Lyn immunoprecipi-
tate was used in an autophosphorylation assay. IL-5–induced tyrosine
phosphorylation of Jak2 (A) and p53/56 Lyn (B, left) kinases. AG490 at 25
and 50 mM concentrations inhibited tyrosine phosphorylation of Jak2 but
not Lyn kinase (n 5 3). AG490 did not affect autophosphorylation of Lyn
kinase at 25 mM but had some inhibitory effects at 50 mM concentration
(B, right).
Figure 3. The effect of Raf-1
antisense ODN on the expres-
sion of Raf-1 and ERK-2 kinases
(A) and phosphorylation of
ERK-2 (B). (A) Purified eosino-
phils were incubated with me-
dium (O), Raf-1 AS (AS), or SS
ODN (SS) for 6 h. The cells
were then washed and lysed.
The lysates were electrophoresed
and immunoblotted with anti–
Raf-1 and anti–ERK-2 antibod-
ies. Raf-1 AS ODN at 5 and 7.5
mM concentrations blocked the expression of Raf-1 but not ERK-2 kinase (n 5 3). The SS ODN did not affect the expression of the kinases. (B) Cells
were pretreated with medium (O) or 7.5 mM concentration of Raf-1 AS (AS) and SS ODN (SS) for 6 h and then stimulated with (1) or without (2)
IL-5. The cells were lysed, immunoprecipitated with an anti-ERK2 antibody, and immunoblotted with an antiphosphotyrosine antibody. IL-5–induced
tyrosine phosphorylation of ERK-2 kinase. Raf-1 AS but not SS ODN inhibited the phosphorylation of ERK-2 kinase (left). The membrane was then
stripped and reprobed with the anti–ERK-2 antibody (right), which showed an equal amount of ERK-2 protein in each lane.425 Pazdrak et al.
AG490 did not affect the expression of CD11b (Fig. 5 B).
Eosinophils treated with AG490 were still able to upregu-
late CD11b expression in response to IL-5. However, her-
bimycin, at 2 mM concentration, inhibited the upregula-
tion of CD11b expression in response to IL-5. Thus, we
conclude that protein tyrosine phosphorylation is impor-
tant for CD11b upregulation, but Lyn and Jak2 kinases are
not essential for this process. However, unlike Lyn AS
Figure 4. The effect of Lyn AS ODN
(A), AG490 (B) and Raf-1 AS ODN
(C) on survival-prolonging activity of
IL-5 on eosinophils. (A) Eosinophils
were pretreated with 10 mM concentra-
tion of Lyn AS and SS ODN or me-
dium (Control) for 6 h. The cells were
then stimulated with (1) or without (2)
IL-5 (10210 M) for 1.5 h. Eosinophil vi-
ability was assessed 32 h later. The con-
trol and Lyn SS-treated cells showed
significant prolongation of eosinophil
survival (n 5 5, *P ,0.01, paired t test)
after IL-5 stimulation. This survival prolonging effect of IL-5 was blocked by pretreatment of cells with Lyn AS ODN. (B) Purified eosinophils were pre-
treated with buffer (Control), AG490 (25 mM) or Herbimycin A (2 mM) for 6 h. The cells were then stimulated with (1) or without (2) IL-5 for 1.5 h.
Eosinophil viability was assessed 32 h later. The IL-5–induced prolongation of eosinophil survival was completely abrogated by both AG490 and Herbi-
mycin A (n 5 5, *P ,0.01). (C) Eosinophils were pretreated with 7.5 mM concentration of Raf-1 AS, SS ODN, or medium (Control) for 6 h. The cells
were then stimulated with (1) or without (2) IL-5 (10210 M) for 1.5 h. Eosinophil viability was assessed 32 h later. The control and SS ODN-treated
cells showed significant prolongation of eosinophil survival (n 5 5, *P ,0.01, paired t test) after IL-5 stimulation. Raf-1 AS ODN completely blocked this
survival prolonging effect of IL-5.
Figure 5. The effect of Lyn
AS ODN (A), AG490 (B), and
Raf-1 AS ODN (C) on CD11b
expression. (A). Eosinophils were
pretreated with medium (Control),
Lyn SS, or AS ODN and then
stimulated with medium or IL-5.
Then the cells were stained with
an anti-CD11b FITC-conjugated
mAb or isotype control mAb and
analyzed by a FACScanÒ. In
control experiments, IL-5 upreg-
ulated the expression of CD11b.
Neither AS nor SS Lyn ODN had
any effect on eosinophil CD11b
expression (n 5 3). (B). Jak2 ki-
nase and CD11b expression. Eo-
sinophils were pretreated with me-
dium (Control), AG490 (25 mM)
or Herbimycin A (2 mM) and
then stimulated with medium or
IL-5. Then the cells were stained
with the anti-CD11b FITC-con-
jugated mAb or isotype control
mAb. In control experiments, IL-5
upregulated the expression of
CD11b. The Jak2 inhibitor
AG490 did not block the upreg-
ulation of CD11b, but a broad
spectrum tyrosine kinase inhibi-
tor Herbimycin A did (n 5 3).
(C) Eosinophils were pretreated
with medium (Control), Raf-1
SS or AS ODN and then stimu-
lated with medium or IL-5.
Then the cells were stained with
the anti-CD11b FITC-conjugated
mAb or isotype control mAb. In
control and Raf-1 SS ODN ex-
periments, IL-5 upregulated the
expression of CD11b. Raf-1 AS
ODN blocked the upregulation
of CD11b by IL-5 (n 5 3).426 Signal–Function Relationship of Lyn, Jak2, and Raf-1 Kinases
ODN and AG490, Raf-1 AS ODN blocked the IL-5–
stimulated upregulation of CD11b on eosinophils (Fig. 5
C). The SS ODN had no effects.
The Effect of AS ODN and AG490 on ECP Release from
Eosinophils. It has been previously reported that tyrosine
phosphorylation is involved in cytokine priming of the re-
spiratory burst and degranulation (18). In our study, we
asked whether Lyn kinase participated in the priming of
eosinophils for ECP release. As a degranulating stimulus we
used phorbol 12-myristate 13-acetate (PMA) at the subop-
timal concentration of 0.1 ng/ml. This dose of PMA did
not induce ECP release above the background level (data
not shown). However, when eosinophils were preincu-
bated with IL-5 for 1.5 h, they became more susceptible to
stimulation with PMA and released three times more ECP
(122 6 13 ng/ml vs. 38 6 5 ng/ml of ECP for unprimed
eosinophils, P ,0.01). Neither Lyn AS nor SS ODN mod-
ified IL-5 priming of ECP secretion (Fig. 6 A). Similar to
Lyn AS ODN, AG490 did not block ECP secretion (Fig. 6
B). The data indicate that Lyn and Jak2 are not required for
IL-5 priming for ECP release.
In contrast to Lyn AS ODN and AG490, Raf-1 AS
ODN almost completely blocked ECP secretion from eo-
sinophils (Fig. 6 C). The SS ODN had no effects. There
are some suggestions from the literature that PMA signaling
may involve Raf-1 kinase. Thus, the PMA stimulation of
cells may be more susceptible to RAF-1 AS inhibition. To
address this issue, we performed experiments using a differ-
ent eosinophil degranulator, PAF, at a subthreshold con-
centration. We observed a similar inhibition of ECP release
from Raf-1 AS ODN-treated cells (132 6 22 ng/ml for
medium-pretreated cells vs. 42 6 6 ng/ml for AS-treated
cells, n 5 3). Thus, although we cannot rule out that Raf-1
is involved in PAF signaling, our results suggest that this ki-
nase is required for transducing signals for ECP release.
Discussion
In this study, we have prepared eosinophils lacking ac-
tive forms of Lyn, Jak2, and Raf-1 kinases and analyzed
their physiologic responses to IL-5. We have made the fol-
lowing observations. (a) IL-5 is unable to inhibit apoptosis
of cells not expressing active Lyn, Jak2, and Raf-1 kinases.
(b) The induction of CD11b expression and ECP secretion
by IL-5 are intact in the absence of Lyn and Jak2 activation.
However, other tyrosine kinases are important for CD11b
upregulation. (c) The IL-5–mediated suppression of eosino-
phil apoptosis, upregulation of CD11b, and ECP secretion
are impaired in eosinophils lacking Raf-1 kinase. Based on
these results, we conclude that Lyn, Jak2, and Raf-1 kinases
are necessary for the antiapoptotic effect of IL-5, whereas
Raf-1 is additionally essential for eosinophil activation and
degranulation. Previously, Lyn kinase was found to be im-
portant for eosinophil survival (11). However, the role of
Lyn in b2 integrin expression and eosinophil degranulation
has been unknown. This is the first report on the impor-
tance of Lyn, Jak2, and Raf-1 kinase in three important
functions of eosinophils. We have established a central role
for Raf-1 kinase in the multifaceted regulation of eosino-
phil function. Further, our work reveals a differential re-
quirement of signaling molecules for survival, adhesion,
and exocytosis of eosinophils.
Eosinophils are terminally differentiated cells that die
rapidly in the tissue or culture due to apoptosis. They ex-
hibit the classical changes in morphology including cyto-
plasmic and nuclear condensation resulting in cell shrink-
age, DNA fragmentation, and loss of nucleoli (20). It is an
important mechanism by which eosinophils are cleared
from the tissue without eliciting inflammation (21). It has
been known for many years that IL-5, GM-CSF, and IL-3
enhance their survival in culture for up to two weeks. The
inhibition of eosinophil apoptosis by interleukins is consid-
ered an important mechanism for the development of
blood and tissue eosinophilia in diseases such as asthma and
other allergic disorders. However, an understanding of the
induction of apoptosis and its inhibition is still fragmentary
and mainly originates from cell lines that may not directly
represent mature hematopoietic cells. Several genes have
been identified that participate either as inducers or repres-
sors of the programmed cell death (22). Among these, Bcl-2
Figure 6. The effect of Lyn
AS ODN (A), AG490 (B), and
Raf-1 AS ODN (C) on ECP re-
lease. (A) Eosinophils were pre-
treated with medium (Control),
Lyn SS or AS ODN and, then,
primed with (1) or without (2)
IL-5. The cells were then chal-
lenged with a suboptimal con-
centration of PMA (0.1 ng/ml)
which by itself did not induce
ECP release. The IL-5–priming
of cells caused significant secretion
of ECP from eosinophils (*P ,0.01, n 5 4). Neither AS nor SS Lyn ODN affected ECP release. (B). Eosinophils were pretreated with medium (Control)
or AG490 (25 mM) and then primed with (1) or without (2) IL-5 as described above. The cells were then challenged with a suboptimal concentration of
PMA (0.1 ng/ml). The IL-5–priming of cells caused significant secretion of ECP from eosinophils (*P ,0.05, n 5 4). Pretreatment of cells with AG490
did not block ECP release. (C) Eosinophils were pretreated with medium (Control), Raf-1 SS or AS ODN and, then, primed with (1) or without (2)
IL-5. The cells were then challenged with PMA (0.1 ng/ml). The IL-5–priming of cells caused significant secretion of ECP from control and SS ODN-
treated eosinophils (*P ,0.05, n 5 4). The Raf-1 AS ODN completely prevented ECP release.427 Pazdrak et al.
and Bax are homologous proteins that have opposing ef-
fects on apoptosis. Bcl-2 serves to prolong cell survival,
whereas Bax acts as an accelerator of apoptosis (23). These
proteins act as ion channels and adaptor proteins regulating
the release of mitochondrial proteins into the cytosol in or-
der to activate the cysteine proteases (caspases) that are the
terminal effectors of apoptosis. Overexpression of Bcl-2 in-
hibits mitochondrial permeability transition, whereas Bax
overexpression induces it. One mechanism of inhibition of
apoptosis by Bcl-2 is its ability to associate with Raf-1,
translocating this kinase from the cytosol to the mitochon-
drial membrane (24). Once there, Raf-1 induces phosphor-
ylation of BAD, a proapoptotic Bcl-2 family protein that
abrogates the cytoprotective functions of Bcl-2 by het-
erodimerizing with it (25). This mechanism could explain
our findings on the requirement of Raf-1 kinase for antiap-
optotic effect of IL-5. In this regard, IL-3 has previously
been shown to induce Bcl-2 in myeloid cell precursors (26).
Another mechanism by which Raf-1 could transduce
the antiapoptotic signal is through activation of down-
stream signaling molecules such as MEK and MAP kinases
and/or NFkB nuclear factor. As we have shown in this
work, inhibition of Raf-1 expression prevents tyrosine
phosphorylation of ERK-2 MAP kinase. MAP kinases are
known to induce c-fos and c-jun (27). The truncation of
the bc receptor at 516 or 626 amino acid residues abolishes
activation of Ras-Raf-MAP, c-fos and c-jun and inhibits
the antiapoptotic effect of GM-CSF (28). Moreover, the
contribution of MAP kinases in regulation of STAT1/3
nuclear factors has recently been reported (29). Because
Raf-1 is essential for both MAP activation and prolonga-
tion of survival, the viability signaling may be linked to
molecules and genes activated by MAP kinases.
There are reports of NFkB activation by Raf-1 kinase
(30). NFkB consists of two subunits (p50 and p65) and ex-
ists in a complex with IkB in resting cells. Activated Raf-1
phosphorylates IkB releasing NFkB that enters the nucleus
and activates various genes carrying the NFkB response el-
ement. Cells lacking NFkB are more sensitive to TNF-
a–induced cytotoxicity, confirming that one of the target
genes for NFkB is a gene encoding a survival factor (31).
Although Raf-1 activation by antiapoptotic cytokines such
as IL-3, GM-CSF, and IL-5 is well documented, the acti-
vation of NFkB in eosinophils has not been investigated.
In this work we confirmed the essential role of Lyn ki-
nase in the antiapoptotic effect of IL-5 as previously re-
ported (11). Lyn kinase is one of the earliest activated ki-
nases after IL-5 stimulation. It is constitutively associated
with the bc receptor for IL-5. It may serve to activate the
cytosolic tyrosine kinase Syk (8, 11). Other potential sub-
strates for Lyn kinase are Raf-1 kinase and SHP2 tyrosine
phosphatase. Our results suggest a dissociation of Lyn from
Raf-1 activation since they have nonoverlapping functions.
This is the first report on the importance of Jak2 kinase
in eosinophil survival. Jak2 kinase is constitutively associ-
ated with the bc subunit of the IL-5 receptor and is acti-
vated upon ligand binding. There are several possible target
molecules for Jak2 kinase: IL-5 bc receptor, STAT nuclear
factors, SHP2 tyrosine phosphatase, and Raf-1. Jak2 is es-
sential for phosphorylation of the receptor as IL-5Rbc
phosphorylation by GM-CSF is abolished in mutant Jak2-
negative BA/F3 cells (13). Interestingly, one of the tyrosine
residues phosphorylated by Jak2 is Y750, which is consid-
ered a viability domain of the IL-5bc receptor. This ty-
rosine residue was found to be necessary for activation of
Shc, p21 ras, Raf-1, and MAP kinases. STAT nuclear fac-
tors are the first described downstream molecules for the
Janus kinase family. The Jak-STAT pathway is considered
critical for cytokine-stimulated proliferation of cells. Their
function in nonproliferating cells such as eosinophils is un-
known. Our results define a role for Jak2 in survival but
not for eosinophil activation.
Human eosinophils constitutively express CD11b/CD18
adhesion molecule. In vitro CD11b/CD18 can be upregu-
lated by a number of stimuli including IL-5, GM-CSF, and
PAF (32, 33). CD11b upregulation on eosinophils is prob-
ably analogous to that on neutrophils, in which CD11b is
rapidly mobilized from cytoplasmic stores and upregulation
does not require de novo protein synthesis (34). Little is
known on signaling events leading to increased expression
of CD11b/CD18. It has been shown that antisense oli-
godeoxynucleotides to the p65 subunit of NFkB block
CD11b expression and alter adhesion properties of differ-
entiated HL-60 granulocytes (35). In our work, we could
not upregulate CD11b expression in eosinophils lacking
Raf-1 kinase. It is possible that the CD11b upregulation
through Raf-1 is linked to NFkB activation.
The suppression of Lyn and Jak2 did not block CD11b
upregulation by IL-5. The result does not imply that ty-
rosine phosphorylation is dispensable for the function, be-
cause treatment of eosinophils with herbimycin A com-
pletely inhibited IL-5–induced upregulation of CD11b.
The data are in agreement with the study of Nishizumi et al.
(36) who found that Lyn-deficient mast cells had impaired
tyrosine phosphorylation and Ca21 mobilization but re-
tained capability for adhesion and degranulation. There are
two possible interpretations of our results. When Lyn is in-
hibited, Jak2 induces Raf-1 activation. Likewise, when
Jak2 is inhibited, Lyn may signal for Raf-1 activation. Al-
ternatively, a third tyrosine kinase (or kinases) is responsible
for Raf-1 signaling. Among the candidates are Fyn, Btk,
Fes, and Syk, all of which have been shown to be activated
by IL-5 (10, 37, 38). Additional pathways may include pro-
tein kinase C.
Recently, it has become evident that CD11b/CD18 is
not simply an adhesion site on the cell surface, but may
modulate a number of cellular processes such as eosinophil
degranulation and superoxide production. For example, su-
peroxide production and release of EDN induced by GM-
CSF is abolished by the treatment of eosinophils with anti-
CD11b and anti-CD18 mAbs (39). Our finding that similar
signaling processes are involved in both CD11b upregula-
tion and degranulation may indicate that these events are
closely linked. We have used IL-5 for eosinophil priming428 Signal–Function Relationship of Lyn, Jak2, and Raf-1 Kinases
and PMA or PAF for the induction of ECP release. Raf-1
appears to control the signaling processes originating from
all these diverse stimuli, leading to ECP secretion. Based on
these observations we believe that Raf-1 is a critical signal
for eosinophil degranulation.
In summary, we have defined specific functions of Lyn,
Jak2, and Raf-1 kinases in eosinophil activation. Eosino-
phils play a pivotal role in asthma and other allergic dis-
eases. The identification of the critical signaling molecules
for eosinophil survival, adhesion, and degranulation will
help develop specific inhibitors for use in allergic and other
eosinophilic disorders.
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